Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
HERON THERAPEUTICS, INC. (HRTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 4 Collard Craig A (CEO) has filed a Form 4 on HERON THERAPEUTICS, INC. /DE/
Txns: Paid exercise price by delivering 692 shares @ $1.65, valued at $1.1k
08/23/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates • Company is well capitalized after signing $50 million working capital credit facility and recent $30 million equity raise • Favorable outcome at Markman hearing in pending CINVANTI® ANDA patent litigation • New management team in place • Reiterating full-year net product sales guidance for the oncology care franchise of $99-$103 million SAN DIEGO, August 14, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and six months ended June 30, 2023 and highlig..."
08/01/2023 D Form D - Notice of Exempt Offering of Securities:
07/25/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/25/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/25/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
07/24/2023 8-K Quarterly results
07/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/17/2023 4 Szekeres David Leslie (EVP, COO) has filed a Form 4 on HERON THERAPEUTICS, INC. /DE/
Txns: Paid exercise price by delivering 2,012 shares @ $1.31, valued at $2.6k
Exercised 1,250 restricted stock units @ $0
Exercised 4,564 restricted stock units @ $0
07/17/2023 4 Peraza Lisa (VP, Chief Accounting Officer) has filed a Form 4 on HERON THERAPEUTICS, INC. /DE/
Txns: Paid exercise price by delivering 860 shares @ $1.31, valued at $1.1k
Exercised 552 restricted stock units @ $0
Exercised 1,933 restricted stock units @ $0
06/30/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/12/2023 3 Forbes William P (EVP, Chief Development Officer) has filed a Form 3 on HERON THERAPEUTICS, INC. /DE/
06/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HERON THERAPEUTICS, INC. Heron Therapeutics, Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware , does hereby certify: FIRST: That, upon the Effective Time, Section A of Article IV of the Certificate of Incorporation of the Corporation shall be amended and restated in its entirety as follows: “A. Authorized Capital. The Corporation is authorized to issue two classes of shares of stock to be designated, respectively, “preferred” and “common.” The total number of shares that the Corporation is authorized to issue is Two Hundred Twenty-Seven Million Five Hundred Thousand . The number of shares of common stock authorized to be issued is Two ...",
"Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer SAN DIEGO, June 12, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appointment of William Forbes, Pharm.D., as Executive Vice President, Chief Development Officer. In addition, Kimberly Manhard, Heron’s Executive Vice President, Drug Development, has resigned from her position. Dr. Forbes joins Heron’s management team and will be responsible for leading clinical and product development for Heron’s acute care and oncology care franchises. “I am thrilled to welcome Bill to the Heron team a..."
05/24/2023 4 Collard Craig A (CEO) has filed a Form 4 on HERON THERAPEUTICS, INC. /DE/
Txns: Paid exercise price by delivering 691 shares @ $1.45, valued at $1k
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates • Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million, Compared to First Quarter Net Product Sales in 2022 • Appointment of Craig Collard as Chief Executive Officer and Jason Grillot as Vice President , Sales and Marketing, of the Acute Care Franchise. SAN DIEGO, May 11, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2023 and highlighted recent corporate updates. First quarter 2023 net product s..."
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/20/2023 8-K Quarterly results
04/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/13/2023 SC 13G GREAT POINT PARTNERS LLC reports a 5.4% stake in HERON THERAPEUTICS, INC.
04/05/2023 4 Collard Craig A (CEO) has filed a Form 4 on HERON THERAPEUTICS, INC. /DE/
Txns: Granted 3,000,000 options to buy @ $1.78, valued at $5.3M
Granted 250,000 restricted stock units @ $0
Granted 4,250,000 options to buy @ $1.78, valued at $7.6M
04/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Heron Therapeutics Announces New CEO and Board Chairman Craig Collard Appointed CEO Adam Morgan Named Chairman of the Board SAN DIEGO, April 3, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the appointment of Craig Collard as Chief Executive Officer , effective today. Mr. Collard succeeds Barry Quart, Pharm.D., who has stepped down as CEO and Chairman of the Board. In addition, as part of the leadership change, the Board elected Adam Morgan as Chairman. Mr. Collard brings more than three decades of experience leading innovative pharmaceutical companies through periods of strategic change to deliver growth ..."
03/29/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Quarterly results
Docs: "Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates - Annual Net Product Sales Across the Company Grew 25% to $107.7 million in 2022, Compared to Annual Net Product Sales in 2021 - - APONVIE™Commercially Launched on March 6, 2023 - - ZYNRELEF® Net Product Sales for Fourth Quarter of 2022 Increased 44% Over Prior Quarter to $3.9 Million - - Oncology Care Franchise Net Product Sales for 2022 Grew 17% Over Prior Year to $97.5 Million – SAN DIEGO, March 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results ..."
03/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Heron Therapeutics Announces Centers for Medicare & Medicaid Services Granted Pass-through Payment Status for APONVIETM, Effective April 1, 2023 SAN DIEGO, March 13, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that CMS has approved transitional pass-through status for APONVIE injectable emulsion, which will be established for three years beginning April 1, 2023 under C-code C9145. APONVIE was approved by the U.S. Food and Drug Administration for intravenous use in adults for the prevention of postoperative nausea and vomiting and became commercially available on March 6, 2023. CMS grants pas..."
03/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Heron Therapeutics Announces U.S. Commercial Launch of APONVIETM for the Management of Postoperative Nausea and Vomiting in Adults - APONVIE, the first and only intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for Postoperative Nausea and Vomiting - - APONVIE is delivered via a single IV push and offers 48 hours of PONV prevention - - Leveraging existing acute care commercial teams across the U.S. - SAN DIEGO, March 6, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced APONVIE injectable emulsion, is now commercially available for intravenous use in adults for the..."
03/02/2023 3 KOTLER KEVIN (Director) has filed a Form 3 on HERON THERAPEUTICS, INC. /DE/
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy